• Gina Keiffer, Zachary French, Lindsay Wilde, Joanne Filicko-O'Hara, Usama Gergis, and Adam F Binder.
• Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
• Front Oncol. 2020 Jan 1; 10: 562625.

AbstractWhile cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.Copyright © 2020 Keiffer, French, Wilde, Filicko-O'Hara, Gergis and Binder.

5 keywords...

hide…